Drugs / Alpha-interferon
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT00761241 | Sep 2008 → Mar 2010 | pancreatic adenocarcinoma | Benaroya Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT00660270 | May 2002 → Nov 2006 | pancreatic adenocarcinoma | Washington University School of Medicine | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT00250796 Comparator | Sep 2000 → Jan 2006 | cancer, liver disorder | University of New Mexico | Completed | No outcome recorded |
| — | NCT04295551 Background | Mar → Jul 2020 | COVID-19 | Jiangxi Qingfeng Pharmaceutical Co. Ltd. | Unknown | No outcome recorded |
| — | NCT04664010 Background | Feb 2020 → Sep 2022 | COVID-19 | Xi'an International Medical Center Hospital | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alpha-interferon | “Alpha-interferon nebulization” NCT04295551 ↗ |
| Route | Subcutaneous | “Alpha-interferon SQ 3,000,000 units on Mondays, Wednesdays, and Fridays during radiation therapy.” NCT00660270 ↗ |